Navigation Links
Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
Date:9/26/2007

RX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end- stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401 (perifosine), a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX- 0401 is currently in Phase 2 clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

About Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd.

Japan Tobacco Inc. is the world's third largest international manufacturer of tobacco products. Since its privatization in 1985, JT has actively diversified its operations into pharmaceuticals and foods. JT entered into the pharmaceutical business in 1987 and established the Central Pharmaceutical Research Institute in 1993. JT is currently engaged in the research and development of new drugs in various areas such as glucose and lipid metabolism, anti-virus, immune disorders and inflammation, and bone metabolism. The company's net sales were 4.769 trillion yen in the fiscal year that ended March 31, 2007.

Torii Pharmaceutical Co., Ltd., established in 1921, has manufactured and distributed ethical pharmaceutical products. In 1998, Torii became a member of the JT Group. To maximally leverage the synergy of the Group,
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. WARF enters licensing agreements for stem cell products
2. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
3. Software company enters health space with RFID solutions on hold
4. Lucigen Corp. enters global licensing agreement
5. Call centers and customer service: The good, the bad, and the clueless
6. GE Healthcare enters agreement with Canadian health authority
7. Data centers: Buyers beware of over-hyped facilities
8. Data centers: Blowing smoke and raising red flags
9. Prodesse enters patent agreement with Roche
10. UW-Madison enters Kauffman grant competition
11. Applied Technology Centers to aid printing and manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... York (PRWEB) July 12, 2014 ... for various reagents used in the life ... driving the life science reagents market towards ... include manufacturers and providers of life science ... Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The ...
(Date:7/11/2014)... 2014 BCC Research ( http://www.bccresearch.com ) ... CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , the global ... nearly $140 billion in 2013. This is estimated to ... compound annual growth rate (CAGR) of 28.6%. , New ... and exciting possibilities within the broader PCR field. The ...
(Date:7/11/2014)... 11, 2014 Cayenne Medical, Inc., ... in the soft tissue reconstruction segment, announced the ... for surgeries involving the shoulder and extremities. The ... novel, inserter-controlled deployment method. The unique delivery eliminates ... anchor pull-out, or anchor displacement (also commonly know ...
(Date:7/10/2014)... July 10, 2014 Understanding the need ... cell lines, and the gap that currently exists in ... expand its industry-leading portfolio of validated ion channel and ... channel-expressing cell lines, as ion channels control many critical ... this activity creates the potential to treat a variety ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
... WILMINGTON, N.C., Sept. 9 Wilmington Pharmaceuticals announced ... granted marketing approval for METOZOLV((TM)) ODT (metoclopramide HCl), an ... gastroesophageal reflux disease (GERD) and diabetic gastroparesis. Wilmington has ... pharmaceutical company with a focus on gastrointestinal disorders. , ...
... , SAN DIEGO, Sept. 9 Orexigen((R) )Therapeutics, Inc. ... obesity, today announced that the Company will be speaking at two upcoming investor ... , Morgan Stanley Global Healthcare Unplugged Conference, ... Time, Location: Grand Hyatt Hotel, New York, ...
... , , , , ... SAN FRANCISCO, Sept. 9 Medivation, Inc. (Nasdaq: MDVN ) ... the following conferences: , , , The ... Eastern Time at the Millennium Broadway Hotel in New York , ...
Cached Biology Technology:Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 2Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 3Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 4Medivation Announces Participation in Upcoming Conferences 2
(Date:7/11/2014)... new report from the Wildlife Conservation Society shows ... help economically valuable species such as lobster, conch, ... help re-colonize nearby reef areas. , The reporttitled ... systematic review of research literature from no-take areas ... Dr. Craig Dahlgren, a recognized expert in marine ...
(Date:7/11/2014)... July 11, 2014--Researchers at the Department of Energy,s ... 100 awards, presented by R&D Magazine in recognition ... "These awards recognize the tremendous value of our ... "Research and development at the National Labs continues ... and pursue the scientific and technological innovations necessary ...
(Date:7/11/2014)... many fires burning in eastern New South Wales, Australia ... , At 03:35 UTC on July 11 (12:35 p.m. ... passed over eastern New South Wales (NSW), the Moderate ... image of the region and spotted smoke (light brown) ... thermal bands, are outlined in red. , The New ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... In Nature, cells and tissues assemble and organize themselves ... their structure and function, such as the elasticity of ... design principles have now been successfully replicated in the ... Inspired Engineering and the School of Engineering and Applied ...
... ANN ARBOR, Mich. Why do some diseases ... the University of Michigan have found neural tissue contains ... susceptibility to a debilitating childhood movement disorder. ... and repetitive movements or abnormal postures. It,s caused by ...
... is an imposing bull always in search of the best ... 4 metres in length belongs to a group of 14 ... scientific assistants since recently. At the beginning of the Antarctic ... the mighty elephant seal bulls were tagged with state-of-the-art satellite ...
Cached Biology News:Harvard's Wyss Institute uses nature's design principles to create specialized nanofabrics 2Harvard's Wyss Institute uses nature's design principles to create specialized nanofabrics 3Neural tissue contains imbalanced levels of proteins, U-M study finds 2Seal bulls in the service of science 2Seal bulls in the service of science 3
... foil heat sealing material is suitable ... a screw down heated lid), especially ... useful method for sample retrieval. Multiple ... existing seal. Ideal for compound management ...
... developed to significantly increase the shelf life ... is increased at room temperature storage conditions ... product is subjected to 0.2 micron filtration, ... This formulation insures consistently high levels of ...
... Blot Strong Antibody Stripping Solution is effective ... that have been developed with chemiluminescence or ... not recommended for stripping colorimetric substrates (TMB, ... possible to effectively remove substrates that precipitate ...
...
Biology Products: